Theratechnologies EBITDA
What is the EBITDA of Theratechnologies?
The EBITDA of Theratechnologies, Inc. is -$22.62
What is the definition of EBITDA?
EBITDA is a company’s earnings before interest, taxes, depreciation, and amortization and is an accounting measure calculated using a company’s net earnings, before interest expenses, taxes, depreciation and amortization are subtracted, as a proxy for a company’s current operating profitability.
ttm (trailing twelve months)
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA of companies in the Health Care sector on TSX compared to Theratechnologies
What does Theratechnologies do?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Companies with ebitda similar to Theratechnologies
- Jaykay Enterprises has EBITDA of -₨22.74
- Virnetx Corp has EBITDA of -$22.74
- Hong Kong Finance Investment has EBITDA of -HKD$22.73
- Dafeng Port Heshun Technology has EBITDA of -HKD$22.70
- Green Organic Dutchman has EBITDA of -CAD$22.69
- PyroGenesis Canada has EBITDA of -CAD$22.68
- Theratechnologies has EBITDA of -$22.62
- Winfull has EBITDA of -HKD$22.62
- Honworld has EBITDA of -¥22.61
- Asia-Pac Investment has EBITDA of -HKD$22.60
- National Access Cannabis has EBITDA of -CAD$22.58
- Ching Lee has EBITDA of -HKD$22.54
- Axon Enterprise Inc has EBITDA of -$22.53